The Patent Trial and Appeal Board’s June 2, 2026 public order in IPR2026-00252 is brief but still worth attention for PTAB practitioners: the Director denied discretionary review, leaving the underlying Board action in place. In practical terms, the decision reinforces how difficult it remains to obtain Director intervention absent a clear policy issue, legal error, or case-specific circumstance warranting extraordinary review.

Because this filing is a “Director Discretionary Decision: Deny,” the key takeaway is procedural rather than merits-driven. The Director did not reopen the panel’s work, did not modify the institution posture, and did not announce a new governing standard. That matters. In the post-Arthrex PTAB landscape, parties increasingly seek Director review as a strategic second look at institution-related rulings and other significant Board determinations. This order signals that such review remains selective and exceptional.

The legal reasoning, as reflected by the nature of the order, appears to be straightforward: the request did not justify discretionary intervention. Where the Director declines review without a substantive merits discussion, the denial generally should not be read as endorsement of every aspect of the panel’s reasoning. Instead, it usually indicates that the case does not present the kind of issue the Director believes warrants centralized correction, clarification, or policy guidance.

For practitioners, the lesson is familiar but important. A request for Director review must do more than argue that the panel got it wrong. The strongest requests identify a conflict with USPTO guidance, a recurring issue with broad systemic consequences, or an apparent departure from controlling law. Absent that, the odds of review are low. This is especially true where the request effectively seeks error correction on a fact-bound record rather than raising a question with institutional significance.

Just as important, this order does not appear to set new precedent or alter existing PTAB discretionary-denial doctrine. There is no indication of a precedential or informative designation, and no announced change to the standards governing institution, rehearing, or Director review. For that reason, its significance lies more in confirming current practice than in reshaping it.

Litigators handling parallel district court and PTAB proceedings should take note: Director review remains a limited tool, not a routine appellate layer. Parties should preserve their best arguments before the panel in the first instance and treat any Director-review request as a targeted policy submission, not merely a rehearing brief in different packaging.

View full case on Docket Alarm